Novartis's secukinumab leads anti-IL17 charge in psoriasis
This article was originally published in Scrip
Executive Summary
Detailed results from Novartis's key Phase III FIXTURE study that pitted its investigational product secukinumab against current biological mainstay Enbrel (etanercept) in psoriasis suggest the product could prove a robust challenger to current treatments.